Pelthos (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics reported Q2 2026 net product revenue of $15.4M, up 45% from Q1. ZELSUVMI prescriptions rose 48% to 11,925 units. Adjusted EBITDA loss narrowed to $5.7M. The company has $24.2M in cash and plans to launch XEPI and Xeglyze in 2027. COGS included a $900K inventory write-off, and SG&A had a $5.3M milestone payment.
How this was made
The 30-second read
Why it matters
The earnings beat provides a fresh data point for valuation models, influencing short-term trading decisions and sector sentiment.
Market read
First-report earnings data for a small-cap biotech, offering actionable insight for traders.
What to watch
Potential future PBM contract expansions and upcoming product launches (XEPI, Xeglyze) could materially improve long-term outlook.
Background
Pelthos Therapeutics reported its Q2 2026 financial results, highlighting rapid growth in its ZELSUVMI product line and upcoming launches.
Ticker impact
Q2 2026 earnings release shows 45% sequential revenue growth and narrowed losses, providing fresh valuation data.
Potential short-term price rally on revenue beat, followed by volatility due to ongoing losses.
Strong top-line growth is a positive catalyst, but negative EBITDA and cash constraints limit upside.
Market effects
Positive signal for niche dermatology biotech sector, may boost peer valuations.
Limited to US biotech investors; no broader regional effect.
Minor global impact; primarily relevant to US small-cap biotech market.
Counterpoint
Despite revenue growth, persistent losses and cash burn could lead to a sell-off if guidance remains weak.
Key entities
- CompanyPelthos Therapeutics
Biopharmaceutical company developing topical treatments.
- ExecutiveScott Plesha
Chief Executive Officer of Pelthos.
